Trifluoperazine, a molecule long used to treat anxiety has been found to interfere with the activity of a protein involved in the pancreatic cancer development process. A study by the Nanotechnology Institute of CNR, unit of Rende, in collaboration with a team of French and Spanish researchers, identified the molecule.
Pancreatic cancer is one of the most lethal tumors. Up until now, the only drugs available to fight it are generic chemotherapy treatments.
The protein Nupr1 belongs to the special class of intrinsically disordered proteins and its involvement in pancreatic cancer pathology was demonstrated in the 1990s by a French team at the National Institute of Health in Marseille. Now, trifluoperazine has been found to be capable of inhibiting this protein.
Ductal carcinoma is the most common pancreatic tumor. Its recovery rates are low, not only due to difficulties of early diagnosis, but also because of the absence of a specific pharmacological treatment.
Completely Arrested Disease Development
Bruno Rizzuti of Cnr-Nanotec in Rende, said:
“The research has been performed starting from the screening of more than 1000 drugs already approved for various therapeutic indications. The combined use of experimental techniques and computer simulations has allowed us to identify some of those drugs capable of interacting with the protein Nupr1. In vitro experiments have afterwards shown that the selected compounds were able to lower the vitality of tumor cells, reduce the ability of migration, and completely suppress the possibility of colony formation.
The most effective compound has been tested in vivo on human pancreatic cancer cells transplanted on mice, and proved to completely arrest the development of the disease. The molecule– known as trifluoperazine, and used until now only for its anti-psychotic action – has demonstrated an antitumor efficacy even higher than the most powerful chemotherapy treatments available. Furthermore, this study shows that this new molecule constitutes not only an alternative to such previously known drugs, but can be combined with them to increase the overall therapeutic effect.”
Additionally, this work is an important step on the research into proteins with disordered structure.
“According to one of the dogmas of classical biology,” says Rizzuti, “the conformation of a protein should be unique and well defined to allow each of these ‘molecular machines’ to carry out a specific function.
Disordered proteins overturn the validity of this principle, and due to their flexible structure, are able to perform multiple functions of cell communication and regulation. However, the absence of well-defined structural elements appeared to be an insurmountable obstacle to proceed to a rational design of selective drugs to hinder their action.”
The demonstration of the possibility of identifying active molecules that inhibit disordered proteins is an important step forward from the point of view of basic research, because it changes completely the scenario in the fight against numerous pathologies.
In fact, it opens up the concrete possibility of multiplying the number of molecular targets that could be hit through a focused use of pharmaceuticals.
José L. Neira et al.
Identification of a Drug Targeting an Intrinsically Disordered Protein Involved in Pancreatic Adenocarcinoma
Scientific Reports (2017). DOI: 10.1038/srep39732
Top Image: Anne Weston, LRI, CRUK, Wellcome Images. Scanning electron micrograph of a cluster of pancreatic cancer cells grown in culture.